| OCTA Insights in CNVM, Morphological Characteristics and Correlation With Structural OCT. (NCT05055973) | Assiut University | 2021-10-01 |
| Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops (NCT04782271) | Sylentis, S.A. | 2021-03-17 |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (NCT04704921) | AbbVie | 2020-12-29 |
| Time Efficiency Comparison of Two IntraVitreal Injection Techniques (NCT04455399) | Peregrine Eye and Laser Institute | 2020-11-09 |
| OCTA Metrics Repeatability and Reproducibility in Different Disorders (NCT04488887) | Tanta University | 2020-08-01 |
| Biomarkers and Choroidal Neovascularization (NCT04439708) | Institut National de la Santé Et de la Recherche Médicale, France | 2020-07-06 |
| Imaging of the Angiofibrotic Switch in Neovascular AMD (NCT03838679) | Medical University of Vienna | 2019-05-01 |
| Effect of Corona Virus on Intravitreal Injections (NCT05494775) | Benha University | 2019-02-01 |
| Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) (NCT03452527) | Iconic Therapeutics, Inc. | 2018-03-26 |
| Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor (NCT03793400) | Changhua Christian Hospital | 2018-03-13 |
| Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging (NCT03105609) | Center for Eye Research Australia | 2017-11-14 |
| Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid (NCT04075188) | Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo | 2017-09-18 |
| Conbercept in Choroidal Neovascularization Secondary to Uveitis (NCT02934841) | Chongqing Medical University | 2016-11-01 |
| Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece (NCT02821247) | Bayer | 2016-07-01 |
| Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD (NCT03024424) | University of Utah | 2016-03-01 |
| Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 (NCT02434328) | Alcon Research | 2015-07-28 |
| Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection (NCT02486484) | Rafic Hariri University Hospital | 2015-03-01 |
| Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (NCT02358889) | Iconic Therapeutics, Inc. | 2015-02-01 |
| Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 (NCT02307682) | Alcon Research | 2014-12-08 |
| Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization (NCT02260687) | Bayer | 2014-12-05 |
| Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (NCT01948830) | Novartis Pharmaceuticals | 2013-12-17 |
| An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. (NCT01908816) | Novartis Pharmaceuticals | 2013-09-26 |
| Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD (NCT01880788) | Sequenom, Inc. | 2012-11-01 |
| Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy (NCT01666236) | Federal University of São Paulo | 2012-09-01 |
| Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study (NCT02015351) | University of Sao Paulo | 2012-09-01 |
| Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome (NCT01578720) | Retina Research Institute, LLC | 2012-06-01 |
| PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) (NCT01445899) | Quark Pharmaceuticals | 2012-02-01 |
| A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye (NCT01531842) | Mid Atlantic Retina | 2011-08-01 |
| SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia (NCT03409250) | Vista Klinik | 2011-06-01 |
| Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration (NCT01334294) | Notal Vision Ltd. | 2011-04-01 |
| Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD (NCT03393767) | Vista Klinik | 2010-12-01 |
| 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) (NCT01175395) | University of Illinois at Chicago | 2010-09-01 |
| Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD (NCT01256580) | Massachusetts Eye and Ear Infirmary | 2010-08-01 |
| Retinal Therapy Guided by 3D OCT Image Analysis (NCT02308215) | Michael Abramoff | 2010-07-01 |
| Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD (NCT01021956) | Steba Biotech S.A. | 2010-06-01 |
| Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (NCT01136252) | Hospital Universitari Vall d'Hebron Research Institute | 2010-05-01 |
| Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study (NCT00855608) | Rafic Hariri University Hospital | 2009-03-01 |
| Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)? (NCT00813514) | Medical University of Vienna | 2009-01-01 |
| Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration (NCT00766337) | Santen Inc. | 2008-12-01 |
| Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD) (NCT00775411) | Allergan | 2008-11-01 |
| Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration (NCT00712491) | Santen Inc. | 2008-09-01 |
| Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia (NCT00967850) | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA | 2008-04-01 |
| Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration (NCT01628354) | University of Melbourne | 2008-02-01 |
| Bevacizumab Effect on Blood Velocity (NCT01298440) | Optical Imaging, Ltd. | 2008-01-01 |
| Use of Spectral OCT in Combination Therapy (NCT01025063) | Barnes Retina Institute | 2008-01-01 |
| Sensitivity of the Home Macular Perimeter (HMP) (NCT00604071) | Notal Vision Ltd. | 2007-11-01 |
| Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD) (NCT00511706) | Allergan | 2007-11-01 |
| Stratus Versus Cirrus OCT in AMD (NCT00568191) | The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery | 2007-10-01 |
| Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy (NCT01256632) | Vision Research Foundation | 2007-10-01 |
| Evaluation of Dosing Interval of Higher Doses of Ranibizumab (NCT00533520) | Brandon G. Busbee, MD | 2007-09-01 |
| Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE) (NCT00510965) | University Hospital, Bonn | 2007-08-01 |
| Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) (NCT00492284) | QLT Inc. | 2007-07-01 |
| Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD (NCT00509548) | TargeGen | 2007-07-01 |
| EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) (NCT00470678) | Novartis | 2007-06-01 |
| Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) (NCT00433017) | Novartis | 2007-05-01 |
| Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration (NCT00473642) | Oklahoma State University Center for Health Sciences | 2007-05-01 |
| Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (NCT00436553) | Novartis | 2007-02-01 |
| Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab (NCT00417703) | Oklahoma State University Center for Health Sciences | 2007-01-01 |
| Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study) (NCT00417846) | Johns Hopkins University | 2007-01-01 |
| Photodynamic and Pharmacologic Treatment of CNV (NCT00570193) | Mid-Atlantic Retina Consultations, Inc. | 2006-12-01 |
| Intravitreal Bevacizumab in Agioid Streaks (NCT00406250) | University of Campania Luigi Vanvitelli | 2006-11-01 |
| Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (NCT00403156) | Vitreous -Retina- Macula Consultants of New York | 2006-11-01 |
| Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV (NCT00429962) | University Hospital, Basel, Switzerland | 2006-07-01 |
| Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT) (NCT00729846) | California Retina Consultants | 2006-05-01 |
| Efficacy of Retreatments With Intravitreal Bevacizumab (NCT00406744) | Asociación para Evitar la Ceguera en México | 2006-05-01 |
| SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (NCT00331864) | Novartis | 2006-04-01 |
| Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD (NCT00426998) | Retinal Consultants Medical Group | 2006-04-01 |
| Macugen for Histoplasmosis (NCT00272766) | Barnes Retina Institute | 2006-02-01 |
| Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration (NCT00304954) | National Eye Institute (NEI) | 2006-02-01 |
| Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration. (NCT00395551) | Ophthalmic Consultants of Boston | 2005-12-01 |
| Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment (NCT00417833) | Asociación para Evitar la Ceguera en México | 2005-12-01 |
| A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (NCT00251459) | Genentech, Inc. | 2005-11-01 |
| Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV) (NCT00370786) | Shahid Beheshti University of Medical Sciences | 2005-11-01 |
| Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks (NCT00599820) | Asociación para Evitar la Ceguera en México | 2005-11-01 |
| A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib (NCT00242580) | Novartis Pharmaceuticals | 2005-09-01 |
| Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD) (NCT00407719) | Johns Hopkins University | 2005-06-01 |
| Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (NCT01423149) | Mateon Therapeutics | 2005-03-01 |
| Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease (NCT00102115) | Light Sciences LLC | 2004-12-01 |
| A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (NCT00363714) | Allergan | 2004-11-01 |
| Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System (NCT00100087) | Theragenics Corporation | 2004-10-01 |
| TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration (NCT00260403) | St. Erik Eye Hospital | 2003-06-01 |
| Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration (NCT01570790) | Johns Hopkins University | 2003-05-01 |
| Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT) (NCT00305630) | Johns Hopkins University | 2002-07-01 |
| Phase II/III Study of Anti-VEGF in Neovascular AMD (NCT00021736) | Eyetech Pharmaceuticals | 2001-07-01 |
| Fluocinolone Implant to Treat Macular Degeneration (NCT00008515) | National Eye Institute (NEI) | 2001-01-01 |
| Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration (NCT00001615) | National Eye Institute (NEI) | 1997-07-01 |
| Macular Photocoagulation Study (MPS) (NCT00000158) | National Eye Institute (NEI) | 1979-02-01 |
| Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV) (NCT01336907) | Notal Vision Ltd. | |